Hyperfine (HYPR) Capital Expenditures Growth (3y) (2024 - 2026)
Hyperfine (HYPR) Capital Expenditures Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | -0.66% |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 9.94% |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 10.89% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 11.78% |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | 12.81% |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 12.62% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 19.51% |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | 9.52% |
| 10 | Hyperfine | 89.22 Mn | 44.45 Mn | 1.98 Mn | -48.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.68% |
| Mar 31, 2026 | 24.22% |
| Dec 31, 2025 | -32.52% |
| Sep 30, 2025 | -35.26% |
| Jun 30, 2025 | 127.82% |
| Mar 31, 2025 | -59.59% |
| Dec 31, 2024 | -52.21% |
| Sep 30, 2024 | -31.54% |
| Jun 30, 2024 | 43.10% |
| Mar 31, 2024 | 133.88% |